期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同剂型美托洛尔对慢性心力衰竭患者B型尿钠肽影响的临床观察 被引量：4

下载PDF
导出
摘要 慢性心力衰竭（CHF）（简称心衰）是一种严重的临床综合征，是各种心脏病的终末阶段。B型尿钠肽（BNP）作为CHF的标志物，已得到广泛认可［1］，而β受体阻滞剂已广泛应用在CHF的治疗中，美托洛尔作为高度选择性β1受体阻滞剂，目前临床上有琥珀酸美托洛尔缓释片及酒石酸美托洛尔片两种剂型，本文旨在观察两种剂型在治疗CHF前后血浆BNP的水平变化。报道如下。
作者 毕磊 曹丹阳
机构地区 北京军区总医院东楼干部病房一科
出处 《浙江临床医学》 2014年第5期762-763,共2页 Zhejiang Clinical Medical Journal
关键词 酒石酸美托洛尔片 慢性心力衰竭患者 B型尿钠肽 临床观察 剂型 选择性Β1受体阻滞剂 琥珀酸美托洛尔缓释片 血浆BNP
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献5

  • 1范姝丽,白小涓,张潇怡,林杰.血浆BNP水平与老年慢性充血性心衰患者心功能状态及预后的关系[J].山东医药,2011,51(5):7-9. 被引量：35
  • 2GaUagher MJ,McCullough PA.The emerging role ofnatriuretic peptides in the diagnosis and treatment ofdeconr pensated heart failue.Curr Heart Fail Rep,2004,1(3):129-135.
  • 3Izumi Y,Okatani H,Shiota M,Effects of metoprolol on epinephrine- induced takotsubo-like left ventricular dysfunction in nonhuman primates.Hypertens Res,2009,32(5):339-346.
  • 4施仲伟.β受体阻滞剂的临床应用价值[J].心血管病学进展,2011,32(1):9-12. 被引量：14
  • 5Wikstrand J,Andersson B,Kendall MJ,et al.Pharmacokinetic con- siderations of formulation :extended-release metoprolol succinate in the treatment of heart failur.J Cardiovasc Pharmacol,2003,41(2):151-157.

二级参考文献35

  • 1施仲伟.阿替洛尔的心脏保护作用缺乏证据[J].中华医学杂志,2005,85(13):928-930. 被引量：9
  • 2无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量：2072
  • 3Braunwald E. Sir James W. Black, MD, FRS 1924-2010 [J]. Circ Res, 2010, 107(1) :3-5.
  • 4Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials [ J ]. BMJ, 2003, 326(7404) :1427-1431.
  • 5Dahlof B, Lindhalm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) [ J ]. Lancet, 1991, 338(8778) :1281-1285.
  • 6Hans, son L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-en- zyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) ran- domised trial[J]. Lancet, 1999, 353(9153) :611-616.
  • 7Hansson L, Linholm LH, Ekbom T, et al. Randomised trial of old and new an- tihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study [ J ]. Lancet, 1999, 354(9192) : 1751-1756.
  • 8Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Dihiazem (NORDIL) Stud- y[J]. Lancet, 2000, 356(9227):359-365.
  • 9UK National Institute for Health and Clinical Excellence. Hypertension: man- agement of hypertension in adults in primary care. Issue date : June 2006, avail- able on November 10 at: www. nice. org. uk/CG034.
  • 10Mancia G, de Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension : The Task Force for the Management of Arterial Hyper- tension of the European Society of Hypertension (ESH) and of the European So- ciety of Cardiology (ESC) [ J ]. J Hypertens, 2007, 25 ( 6 ) : 1105 -1187.

共引文献47

同被引文献49

  • 1Richard W Troughton, Christopher M Frampton, Timothy G Yandle, et al. Treatment of heart failure guided by plasma aminoterminal brain na- triuretic peptide( N-BNP ) concentrations [ J ]. The Lancet, 2000,355 (9210) :1126-1130.
  • 2Vuoheenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease [ J ]. Advances in Clinical Chemistry,2005 ( 40 ) : 1-36.
  • 3Dries DL, Stevenson LW. Brain natriuretic peptide as bridge to therapy for heart failure [ J ]. The Lancet,2000,355 (9210) : 1112-1113.
  • 4Ishii J, Nomura M, Nakamura Y. Risk stratification using a combination of cardiac troponin T and briain natriuretic peptide in patients hospi- talized for worsening chronic heart failure [ J ]. American Journal of Cardiology ,2002,89 (6) :691-695.
  • 5Maisel A. B-type natriuretic peptide levels:Diagnostic and prognostic in congestive heart failure : what is next [ J ]. Circulation, 2002,105 ( 20 ) : 2328 -2331.
  • 6McCullough PA, Sandberg KR. B-type natriuretie peptide and renal disease [ J ]. Heart Failure Reviews,2003,8 (4) :355-358.
  • 7Miller WL, Hartman KA. Response of novel biomarkers to BNP infu- sion in patients with deeompensated heart failure : a multimarker para- digm[J]. J Cardiovasc Transl Res,2009,2(4) :526-535.
  • 8Hardy CI, Weiss RG, Bottomley PA. Altered myocardial high energy phosphate metabolites in patients with dilated cardiomyopathy[ J ]. A- merican Heart Journal, 1991,122 (3) :795-801.
  • 9无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量：3686
  • 10史大卓.慢性心力衰竭的发病机制及中西医治疗[J].中国中西医结合杂志,2008,28(11):1053-1056. 被引量：17

二级引证文献62

浙江临床医学
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部